Vera Therapeutics (VERA) stock falls as Otsuka (OTSKF) updates on its IgA nephropathy therapy sibeprenlimab, which rivals ...

Shares of Vera Therapeutics Inc. (NASDAQ: VERA) tumbled by 17% as the market responded to updates on a competing drug that ...

Goldman Sachs notes that Vera Therapeutics (VERA) shares are down 18% and underperforming the biotech group today following earnings results ...

Wells Fargo notes that Vera Therapeutics (VERA) shares are down about 20% today, which the firm attributes to competitor Otsuka saying they ...

Vera Therapeutics Inc. (VERA) shares tumbled to a 52-week low, touching down at $31.64 amidst a challenging market environment. According to InvestingPro data, this represents a significant drop from ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on February 8, 2025, the Compensation Committee granted ...

Read Our Latest Analysis on VERA Vera Therapeutics Stock Down 0.5 % The company has a market capitalization of $2.19 billion, a P/E ratio of -13.25 and a beta of 1.15. The company has a debt-to ...

Shares of NASDAQ VERA opened at $37.48 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a 50 day simple moving ...

Check the time stamp on this data. Updated AI-Generated Signals for Vera Therapeutics Inc. (VERA) available here: VERA. Type ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vera Therapeutics BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement ...